B. Riley Securities Downgrades Longboard Pharmaceuticals to Neutral, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has downgraded Longboard Pharmaceuticals from Buy to Neutral, while raising the price target from $45 to $60.
October 14, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B. Riley Securities downgraded Longboard Pharmaceuticals from Buy to Neutral, but increased the price target from $45 to $60, indicating a mixed outlook.
The downgrade from Buy to Neutral suggests a less optimistic view on the stock's potential, which could lead to a neutral short-term impact on the stock price. However, the raised price target to $60 indicates some positive expectations, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100